Showing results (121-130 of 173) with videos related to
Sort By:
Pageof 18
Journal of Neuro-Oncology|May 12, 2009
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannomaScott R Plotkin, Chris Halpin, Jaishri O Blakeley, et al.Neurosurgery|August 29, 2003
Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicityDamien C Weber, Annie W Chan, Marc R Bussiere, et al.Leukemia Research|May 14, 2023
Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemiaEvan Atchley, Taylor M Weis, Andriy Derkach, et al.Neuro-Oncology Advances|May 22, 2023
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2Justin T Jordan, Christina C Orr, Raquel D Thalheimer, et al.Neurosurgical Focus|June 1, 2026
Evolving approaches to craniopharyngioma diagnosisIris P van Mullem, Isabel A Wood, Ye Rim Chang, et al.Neurosurgery|July 4, 2014
Cervical spondylotic myelopathy surgical trial: randomized, controlled trial design and rationaleZoher Ghogawala, Edward C Benzel, Robert F Heary, et al.Journal of Neurosurgery|November 26, 2016
Targeted sequencing of SMO and AKT1 in anterior skull base meningiomasMatthew R Strickland, Corey M Gill, Naema Nayyar, et al.Neuro-Oncology|November 25, 2015
Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological gradeWilliam L Hwang, Ariel E Marciscano, Andrzej Niemierko, et al.Neurosurgery|February 21, 2018
A Review of Industry Funding in Randomized Controlled Trials Published in the Neurosurgical Literature-The Elephant in the RoomNickalus R Khan, Hassan Saad, Chesney S Oravec, et al.Acta Neuropathologica Communications|October 22, 2020
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnosticErik A Williams, Sandro Santagata, Hiroaki Wakimoto, et al.Pageof 18